Abbott Laboratories shares are trading close to a resistance zone which currently limits any upside potential. We expect that this level will be broken due to the stock's technical chart pattern. Investors have an opportunity to buy the stock and target the $ 125.
The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
The company has solid fundamentals for a short-term investment strategy.
The company returns high margins, thereby supporting business profitability.
Over the past year, analysts have regularly revised upwards their sales forecast for the company.
Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The stock is in a well-established, long-term rising trend above the technical support level at 88.71 USD
The share is close to its long-term resistance in weekly data. Therefore, the potential should be limited. However, a further bullish movement when crossing this resistance will be a positive signal.
Technically, the stock approaches a strong medium-term resistance at USD 114.42.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
With an enterprise value anticipated at 6.05 times the sales for the current fiscal year, the company turns out to be overvalued.
With a 2020 P/E ratio at 45.97 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
Disclaimer: The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.